171 related articles for article (PubMed ID: 8893887)
21. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Vici P; Capomolla E; Foggi P; Carpano S; Conti F; Paoletti G; Cauchi C; Giacinti L; Leonetti C; Giannarelli D; Lopez M
J Exp Clin Cancer Res; 2006 Mar; 25(1):39-44. PubMed ID: 16761616
[TBL] [Abstract][Full Text] [Related]
22. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
25. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
26. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
28. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
[TBL] [Abstract][Full Text] [Related]
29. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Blackstein M; Vogel CL; Ambinder R; Cowan J; Iglesias J; Melemed A
Oncology; 2002; 62(1):2-8. PubMed ID: 11810037
[TBL] [Abstract][Full Text] [Related]
31. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra HS; Benoehr C; Pacini M; Bonadonna G; Diehl V
J Clin Oncol; 2000 Jul; 18(13):2615-9. PubMed ID: 10893294
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
34. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt RP; Bezwoda WR; Falkson G; Goedhals L; Hacking D; Rugg TA
J Clin Oncol; 1994 Aug; 12(8):1535-40. PubMed ID: 8040664
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
D'Agostino G; Amant F; Berteloot P; Scambia G; Vergote I
Gynecol Oncol; 2003 Mar; 88(3):266-9. PubMed ID: 12648573
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
[TBL] [Abstract][Full Text] [Related]
39. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
40. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
